Relai Neuro CEO Appointed as Interim CEO to Avail Scientific

Rhea-AI Summary

MOBILE LADS CORP, operating as AVAIL SCIENTIFIC (OTC PINK:MOBO), has announced the appointment of Dr. James Thompson as Interim CEO following the Letter of Intent to acquire Relai Neuro, where he serves as CEO. Dr. Thompson brings extensive experience in neurological testing and medical technology, aiming to strengthen Avail's mission in psychedelic medicine research. Current CEO Michael Paul will remain as President and Chairman. The acquisition aims to combine resources for developing treatments addressing addiction and mental health challenges. Avail is positioned to lead in providing data-driven solutions for effective therapeutic programs.

Positive

• Appointment of Dr. James Thompson as Interim CEO, expected to enhance leadership and strategic partnerships.
• Acquisition of Relai Neuro aims to strengthen Avail's position in neurological testing and psychedelic medicine.
• Focus on addressing addiction and mental health issues aligns with growing market interest in psychedelic therapeutics.

Negative

• None.

TORONTO, ON / ACCESSWIRE / January 26, 2023 / MOBILE LADS CORP, doing business as AVAIL SCIENTIFIC ("AVAIL") / (OTC PINK:MOBO) is pleased to announce Dr. James Thompson will be appointed as Interim CEO of Avail Scientific. This appointment follows Avail's January 10th, 2023 announcement of having signed a Letter of Intent that outlined the terms for the acquisition of Relai Neuro at which Dr. Thompson is currently CEO.

Dr. Thompson's professional experience in neurological testing and analytics, his work in founding, growing, and consulting with medical technology companies, and his passion for the mental health space will be instrumental in guiding Avail Scientific's pursuit of supporting psychedelic medicine research and treatments through neurological testing, data analytics, and data management.

Dr. Thompson states, "I am excited to help lead Avail Scientific. One of my first goals will be to build out our management team as well as to establish key strategic partnerships over the next few months in order to position us to achieve our collective mission."

Current CEO, Michael Paul will retain his role as President and Chairman of the Board of Directors of Avail. "We are excited to have Dr. Thompson take on the Interim CEO role at Avail as it aligns itself with Relai Neuro to become a much stronger single company. We are confident that Dr. Thompson can help drive the company toward its goal of becoming a world leader in the development of psychedelic therapeutics for the treatment of addiction & mental health issues," said Michael Paul.

Relai Neuro provides neurological testing and data management to rehab and mental health treatment centers in Florida.

MOBILE LADS' mandate is to support psychedelic medicine research and treatments through neurological testing, data analytics, and data management.

RelaiNeuro - www.relaineuro.com

About Avail Scientific

Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse.

We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally.

Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.

Contact:

aware@availscientific.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

SOURCE: Mobile Lads, Corp.

View source version on accesswire.com:
https://www.accesswire.com/736885/Relai-Neuro-CEO-Appointed-as-Interim-CEO-to-Avail-Scientific

FAQ

Who is the new Interim CEO of MOBO?

Dr. James Thompson has been appointed as the Interim CEO of MOBILE LADS CORP (MOBO).

What is the significance of the acquisition of Relai Neuro for MOBO?

The acquisition is expected to strengthen MOBO's capabilities in neurological testing and support its mission in psychedelic medicine.

What are the main goals of Avail Scientific under Dr. Thompson's leadership?

Dr. Thompson aims to build a management team and establish strategic partnerships to enhance Avail's mission in psychedelic medicine.

How does MOBO plan to tackle addiction and mental health issues?

MOBO plans to provide data-driven solutions and effective therapeutic programs to address addiction and mental health challenges.

What is the background of Dr. James Thompson related to MOBO?

Dr. James Thompson has extensive experience in neurological testing and medical technology and was the CEO of Relai Neuro before his appointment at MOBO.